| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 4.272.432 | 4.526.257 | 4.768.590 | 244.141 | 94.328 | 32.586 | - | - | - | - |
| Total Income - EUR | 4.546.299 | 4.629.672 | 4.978.888 | 294.482 | 101.489 | 32.590 | - | - | - | - |
| Total Expenses - EUR | 4.528.895 | 4.629.728 | 4.975.119 | 481.543 | 92.276 | 38.024 | - | - | - | - |
| Gross Profit/Loss - EUR | 17.403 | -56 | 3.770 | -187.062 | 9.213 | -5.435 | - | - | - | - |
| Net Profit/Loss - EUR | 14.619 | -751 | 824 | -187.062 | 7.761 | -6.560 | - | - | - | - |
| Employees | 11 | 18 | 12 | 7 | 2 | 1 | - | - | - | - |
Check the financial reports for the company - Nexus Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 36.913 | 54.293 | 73.382 | 6.437 | 827 | 1.567 | - | - | - | - |
| Current Assets | 535.148 | 705.487 | 422.989 | -11.302 | -21.145 | 48.629 | - | - | - | - |
| Inventories | 392.278 | 268.916 | 312.676 | 23.718 | 24.669 | 38.021 | - | - | - | - |
| Receivables | 130.585 | 360.756 | 40.341 | -45.986 | -47.063 | 8.172 | - | - | - | - |
| Cash | 12.285 | 75.815 | 69.972 | 10.967 | 1.249 | 2.435 | - | - | - | - |
| Shareholders Funds | 22.083 | 21.107 | 21.574 | -165.884 | -154.891 | -158.514 | - | - | - | - |
| Social Capital | 227 | 225 | 221 | 217 | 232 | 227 | - | - | - | - |
| Debts | 550.153 | 740.010 | 475.527 | 161.385 | 134.665 | 208.787 | - | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4645 - 4645" | |||||||||
| CAEN Financial Year |
4645
|
|||||||||
Comments - Nexus Pharma S.r.l.